Masato Kanda, Toshio Nagai, Toshinao Takahashi, Mei Lan Liu, Naomichi Kondou, Atsuhiko T. Naito, Hiroshi Akazawa, Goro Sashida, Atsushi Iwama, Issei Komuro, Yoshio Kobayashi
PLOS ONE 11(5) e0156562 2016年5月 査読有り
Cardiac stem cells or precursor cells regenerate cardiomyocytes; however, the mechanism underlying this effect remains unclear. We generated CreLacZ mice in which more than 99.9% of the cardiomyocytes in the left ventricular field were positive for 5-bromo-4-chloro-3-indolyl-beta-D-galactoside (X-gal) staining immediately after tamoxifen injection. Three months after myocardial infarction (MI), the MI mice had more X-gal-negative (newly generated) cells than the control mice (3.04 +/- 0.38/mm(2), MI; 0.47 +/- 0.16/mm(2), sham; p < 0.05). The cardiac side population (CSP) cell fraction contained label-retaining cells, which differentiated into X-gal-negative cardiomyocytes after MI. We injected a leukemia inhibitory factor (LIF)-expression construct at the time of MI and identified a significant functional improvement in the LIF-treated group. At 1 month after MI, in the MI border and scar area, the LIF-injected mice had 31.41 +/- 5.83 X-gal-negative cardiomyocytes/mm(2), whereas the control mice had 12.34 +/- 2.56 X-gal-negative cardiomyocytes/mm(2) (p < 0.05). Using 5-ethy-nyl-2'-deoxyurinide (EdU) administration after MI, the percentages of EdU-positive CSP cells in the LIF-treated and control mice were 29.4 +/- 2.7% and 10.6 +/- 3.7%, respectively, which suggests that LIF influenced CSP proliferation. Moreover, LIF activated the Janus kinase (JAK) signal transducer and activator of transcription (STAT), mitogen-activated protein kinase/extracellular signal-regulated (MEK) extracellular signal-regulated kinase (ERK), and phosphatidylinositol 3-kinase (PI3K)-AKT pathways in CSPs in vivo and in vitro. The enhanced green fluorescent protein (EGFP)-bone marrow-chimeric CreLacZ mouse results indicated that LIF did not stimulate cardiogenesis via circulating bone marrow-derived cells during the 4 weeks following MI. Thus, LIF stimulates, in part, stem cell-derived cardiomyocyte regeneration by activating cardiac stem or precursor cells. This approach may represent a novel therapeutic strategy for cardiogenesis.